



Chimerix, Inc.
 Investor Relations Department
 2505 Meridian Pkwy
 Suite 100
 Durham, NC 27713
 United States

Visit IR website [↗](#)
 Sign-up for Email alerts [↗](#)

NASDAQ: CMRX

Last Trade:	4.35
Trade Time:	4:00 PM ET Aug 18, 2017
Change:	-0.05 ↓ (-1.136%)
Day Range	4.31 - 4.44
52-Week Range	3.66 - 6.64
Volume	140,130


Stock information is provided by eSignal, stock charts provided by EDGAR Online. Stock data is delayed approximately 20 minutes.

Company Profile

Chimerix is a biopharmaceutical company dedicated to discovering, developing and commercializing medicines that improve outcomes for immunocompromised patients. Chimerix's proprietary lipid conjugate technology has produced brincidofovir; CMX157, which was licensed to ContraVir Pharmaceuticals; and earlier-stage clinical candidates. Chimerix recently announced a new clinical candidate, CMX521, for the treatment and/or prevention of norovirus.

... [\(more\)](#)

Stock Performance



Press Releases [\[View all \]](#)

- Aug 7, 2017*
[Chimerix Announces Second Quarter 2017 Financial Results](#)
- Jul 31, 2017*
[Chimerix to Announce Second Quarter 2017 Financial Results on August 7, 2017](#)
- May 9, 2017*
[Chimerix Announces First Quarter 2017 Financial Results](#)
- May 2, 2017*
[Chimerix to Announce First Quarter 2017 Financial Results on May 9, 2017](#)
- Apr 20, 2017*
[Chimerix to Host Annual Investor Update on April 27, 2017](#)

Financials [\[View all \]](#)

- [Second Quarter Financial Results](#)
- Mar 2, 2017*
[Annual Report \(10-K\)](#)
- May 1, 2017*
[Proxy Statement \(DEF 14A\)](#)
- Aug 7, 2017*
[Quarterly Report \(10-Q\)](#)
- May 9, 2017*
[Quarterly Report \(10-Q\)](#)
- Nov 7, 2016*
[Quarterly Report \(10-Q\)](#)